Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial

Patient Information

The patient population in this phase 2 randomized clinical trial (NCT06501638) consisted of 241 symptomatic adults presenting with frequent premature atrial contractions (PACs). Inclusion criteria required a mean 24-hour PAC count of at least 1,000 as documented by Holter monitoring. These patients frequently reported symptoms such as palpitations, chest discomfort, and fatigue, significantly impacting their quality of life. Atrial arrhythmias, particularly frequent PACs, are clinically relevant as they are independent predictors of atrial fibrillation (AF), stroke, and heart failure. Despite these risks, pharmacological options for PAC suppression have traditionally been limited to non-specific beta-blockers or antiarrhythmic drugs that target ion channels, often with significant side-effect profiles.

Diagnosis

The diagnosis for all participants was confirmed using 24-hour ambulatory Holter monitoring. The key diagnostic finding was a high burden of ectopy originating from the atria, defined as a PAC count ≥1,000 per 24 hours. Physical examination in such cases often reveals an irregular pulse (extra beats or pauses). The diagnosis focuses on differentiating PACs from other forms of ectopy and ensuring the symptoms are directly attributable to the rhythm disturbance. In this cohort, patients were symptomatic, reinforcing the clinical necessity for intervention to alleviate symptoms and potentially mitigate the long-term risk of developing atrial fibrillation.

Differential Diagnosis

During the screening and diagnostic phase, several conditions were considered and ruled out to ensure the efficacy and safety profile of memantine could be accurately assessed. The differential diagnoses included:

• Premature Ventricular Contractions (PVCs): Distinguished from PACs by the width of the QRS complex and the presence or absence of a preceding P-wave on the ECG.
• Atrial Fibrillation (AF): Characterized by a lack of discernible P-waves and an irregularly irregular R-R interval; while PACs can trigger AF, the baseline diagnosis for this study required frequent ectopy rather than sustained AF.
• Supraventricular Tachycardia (SVT): Typically involves a more sustained rapid heart rate rather than isolated premature beats.
• Secondary Causes of Ectopy: Hyperthyroidism, electrolyte imbalances (hypokalemia or hypomagnesemia), excessive caffeine intake, and chronic stress were evaluated to ensure that the PAC burden was not secondary to reversible external factors.

Treatment and Management

Patients were randomly assigned in a double-blind fashion to receive either memantine or a placebo for a total duration of 6 weeks. Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist traditionally used in the management of Alzheimer’s disease, was selected based on preclinical evidence suggesting its role in suppressing atrial arrhythmias via the cardiac glutamatergic system. Unlike standard antiarrhythmics that target sodium, potassium, or calcium ion channels, memantine targets NMDA receptors which regulate atrial electrophysiology. This represents a novel, non-ion channel-based therapeutic strategy. The primary end point focused on the percentage change in the mean 24-hour PAC count from the baseline to the end of the treatment period.

Outcome and Prognosis

The trial results demonstrated a significant therapeutic benefit for patients treated with memantine. Among the 241 patients in the efficacy analysis, those in the memantine group experienced a reduction in PAC count that was 47.1 percentage points greater than that of the placebo group (P=0.0045).

Key secondary outcomes were equally compelling:

• Responder Rate: 52.4% of patients in the memantine group achieved a reduction of ≥50% in PAC burden, compared to only 23.1% in the placebo group (P<0.0001).
• Atrial Tachycardia: Memantine significantly reduced the burden of nonsustained atrial tachycardia by a difference of 30.98 percentage points compared to placebo (P=0.0043).
• New-Onset Atrial Fibrillation: Most notably, the cumulative incidence of new-onset AF was significantly lower in the memantine group (4.8%) versus the placebo group (23.9%; P<0.0001).

From a safety perspective, no clinically meaningful differences were noted in electrocardiographic intervals (such as QTc) or left ventricular function. No drug-related serious adverse events occurred, indicating a favorable safety profile for cardiac patients.

Discussion

This phase 2 trial provides the first clinical evidence that memantine can effectively suppress atrial ectopy and reduce the burden of atrial tachyarrhythmias. The significance of this study lies in its validation of the cardiac glutamatergic system as a viable therapeutic target. While the NMDA receptor is primarily known for its role in the central nervous system, experimental studies have identified a functional glutamatergic system within the heart. These receptors appear to play a critical role in regulating atrial electrophysiology and, when over-activated, may contribute to the development of arrhythmias.

By repurposing memantine—a drug with a well-established safety profile—clinicians may have a new tool to manage symptomatic PACs. PACs are more than a nuisance; their presence is a marker of atrial remodeling and a precursor to more severe conditions like AF and heart failure. The dramatic reduction in new-onset AF observed in this study suggests that targeting PACs with memantine might actually provide an upstream preventive benefit against the progression of atrial disease.

Future research should focus on long-term outcomes and the potential for memantine to be used in broader populations, including those with established atrial fibrillation or those undergoing catheter ablation. This study marks a paradigm shift from traditional ion-channel blockers toward a more targeted, receptor-based approach in cardiac rhythm management.

References

Shen Y, Zeng C, Sun Y, et al. Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial. Circulation. 2026; PMID: 41853846. DOI: https://pubmed.ncbi.nlm.nih.gov/41853846/